Pharma Mar, S.A.
PHMMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $174,855 | $158,153 | $196,343 | $229,831 |
| % Growth | 10.6% | -19.5% | -14.6% | – |
| Cost of Goods Sold | $8,183 | $9,613 | $13,639 | $16,437 |
| Gross Profit | $166,672 | $148,540 | $182,704 | $213,394 |
| % Margin | 95.3% | 93.9% | 93.1% | 92.8% |
| R&D Expenses | $103,502 | $99,302 | $83,449 | $72,170 |
| G&A Expenses | -$2,853 | $18,263 | $19,022 | $17,371 |
| SG&A Expenses | -$2,679 | $41,805 | $43,241 | $39,739 |
| Sales & Mktg Exp. | $174 | $23,542 | $24,219 | $22,368 |
| Other Operating Expenses | $59,381 | $11,260 | $11,579 | $9,134 |
| Operating Expenses | $160,204 | $152,367 | $138,269 | $121,043 |
| Operating Income | $6,468 | -$3,827 | $44,071 | $92,447 |
| % Margin | 3.7% | -2.4% | 22.4% | 40.2% |
| Other Income/Exp. Net | $5,517 | $204 | -$281 | -$6,356 |
| Pre-Tax Income | $11,985 | -$3,623 | $43,790 | $95,129 |
| Tax Expense | -$14,140 | -$4,760 | -$5,566 | $2,270 |
| Net Income | $26,125 | $1,137 | $49,356 | $92,859 |
| % Margin | 14.9% | 0.7% | 25.1% | 40.4% |
| EPS | 1.49 | 0.064 | 2.73 | 5.14 |
| % Growth | 2,246.5% | -97.7% | -46.9% | – |
| EPS Diluted | 1.49 | 0.064 | 2.73 | 5.13 |
| Weighted Avg Shares Out | 17,539 | 17,900 | 18,050 | 18,070 |
| Weighted Avg Shares Out Dil | 17,562 | 17,916 | 18,063 | 18,085 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,665 | $4,103 | $875 | $370 |
| Interest Expense | $2,469 | $2,416 | $2,376 | $3,373 |
| Depreciation & Amortization | $6,773 | $5,756 | $5,900 | $5,583 |
| EBITDA | $21,227 | $4,549 | $52,066 | $104,085 |
| % Margin | 12.1% | 2.9% | 26.5% | 45.3% |